Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of EBITDA Margin data on record, last reported at 1998.77% in Q4 2025.

  • For Q4 2025, EBITDA Margin changed N/A year-over-year to 1998.77%; the TTM value through Dec 2025 reached 6034.5%, up 2268754.0%, while the annual FY2025 figure was 6034.5%, 2268754.0% up from the prior year.
  • EBITDA Margin reached 1998.77% in Q4 2025 per CRNX's latest filing, up from 90572.03% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1163.75% in Q1 2022 and bottomed at 90572.03% in Q3 2025.
  • Average EBITDA Margin over 5 years is 15168.89%, with a median of 9717.66% recorded in 2022.
  • The widest YoY moves for EBITDA Margin: up 739241bps in 2025, down -1593236bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 2890.91% in 2021, then crashed by -114bps to 6193.51% in 2022, then plummeted by -164bps to 16363.58% in 2023, then dropped by -14bps to 18645.36% in 2024, then surged by 89bps to 1998.77% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 1998.77% in Q4 2025, 90572.03% in Q3 2025, and 11252.96% in Q2 2025.